{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:28:11Z","timestamp":1785558491218,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007394","name":"Association Laurette Fugain","doi-asserted-by":"publisher","award":["ALF 2021\/09"],"award-info":[{"award-number":["ALF 2021\/09"]}],"id":[{"id":"10.13039\/100007394","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011773","name":"R\u00e9gion Bourgogne-Franche-Comt\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011773","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006332","name":"Association Laurette Fugain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006332","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence nationale de la recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0021-LipSTIC"],"award-info":[{"award-number":["ANR-11-LABX-0021-LipSTIC"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.omton.2025.201097","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:17:23Z","timestamp":1763763443000},"page":"201097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities"],"prefix":"10.1016","volume":"33","author":[{"given":"Charles-Fr\u00e9d\u00e9ric","family":"Mantion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeha","family":"Biichl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwena\u00ebl","family":"Rolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agathe","family":"Lejeune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Labaigt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"B\u00f4le-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Royer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Renosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Adotevi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Loyon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Fredon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6930-9554","authenticated-orcid":false,"given":"Francine","family":"Garnache-Ottou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2025.201097_bib1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201097_bib2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201097_bib3","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201097_bib4","doi-asserted-by":"crossref","first-page":"8901","DOI":"10.2147\/CMAR.S321202","article-title":"Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience","volume":"13","author":"Schaefer","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.omton.2025.201097_bib5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omton.2025.201097_bib6","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/17474086.2021.1988848","article-title":"Targeting CD123 in BPDCN: an emerging field","volume":"14","author":"DiPippo","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.omton.2025.201097_bib7","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/17474086.2021.1935855","article-title":"CD123-targeted therapy in acute myeloid leukemia","volume":"14","author":"Espinoza-Gutarra","year":"2021","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.omton.2025.201097_bib8","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytometry, Part B"},{"key":"10.1016\/j.omton.2025.201097_bib9","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.3390\/cancers12113087","article-title":"CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies","volume":"12","author":"El Achi","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201097_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2050-7771-2-4","article-title":"CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies","volume":"2","author":"Testa","year":"2014","journal-title":"Biomark. Res."},{"key":"10.1016\/j.omton.2025.201097_bib11","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1038\/s41375-020-0777-1","article-title":"CD28\/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm","volume":"34","author":"B\u00f4le-Richard","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201097_bib12","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.3390\/cancers14133168","article-title":"Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells","volume":"14","author":"Ca\u00ebl","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2025.201097_bib13","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/2326-6066.CIR-23-0548","article-title":"Impact of scFv on Functionality and Safety of Third-Generation CD123 CAR T Cells","volume":"12","author":"Fredon","year":"2024","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.201097_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/jha2.149","article-title":"BPDCN: When polychemotherapy does not compromise allogeneic CD123 CAR-T cell cytotoxicity","volume":"2","author":"Poussard","year":"2021","journal-title":"eJHaem"},{"key":"10.1016\/j.omton.2025.201097_bib15","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/blood-2005-03-1072","article-title":"Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia","volume":"106","author":"Taussig","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201097_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/icb.1996.1","article-title":"IL-3 receptor expression, regulation and function in cells of the vasculature","volume":"74","author":"Korpelainen","year":"1996","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omton.2025.201097_bib17","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.2147\/OTT.S205678","article-title":"IFN-\u03b3 and TNF-\u03b1 aggravate endothelial damage caused by CD123-targeted CAR T cell","volume":"12","author":"Sun","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.omton.2025.201097_bib18","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2025.201097_bib19","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.ymthe.2017.01.011","article-title":"Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells","volume":"25","author":"Diaconu","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2025.201097_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.omton.2025.201097_bib21","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","article-title":"Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity","volume":"135","author":"Dufva","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201097_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T cell function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omton.2025.201097_bib23","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omton.2025.201097_bib24","doi-asserted-by":"crossref","first-page":"17608","DOI":"10.18632\/oncotarget.24807","article-title":"A Jurkat 76 based triple parameter reporter system to evaluate TCR functions and adoptive T cell strategies","volume":"9","author":"Rosskopf","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.omton.2025.201097_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2024.103529","article-title":"Protocol for production of tonic CAR T cells with dasatinib","volume":"6","author":"Rosselle","year":"2025","journal-title":"STAR Protoc."},{"key":"10.1016\/j.omton.2025.201097_bib26","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaccao.2021.09.009","article-title":"Reversible Myocardial Edema Secondary to Tagraxofusp-Induced Capillary Leak Syndrome","volume":"3","author":"Mouhayar","year":"2021","journal-title":"JACC. CardioOncol."},{"key":"10.1016\/j.omton.2025.201097_bib27","first-page":"44","article-title":"Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm","volume":"109","author":"Luskin","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.201097_bib28","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1056\/NEJMoa1815105","article-title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","volume":"380","author":"Pemmaraju","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2025.201097_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3324\/haematol.2018.205252","article-title":"CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia","volume":"104","author":"Angelova","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.omton.2025.201097_bib30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1470-2045(23)00674-5","article-title":"Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody\u2013drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1\/2 study","volume":"25","author":"Daver","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omton.2025.201097_bib31","doi-asserted-by":"crossref","first-page":"PR14","DOI":"10.1158\/2326-6074.TUMIMM18-PR14","article-title":"Abstract PR14: CD123CAR displays clinical activity in relapsed\/refractory (r\/r) acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN): Safety and efficacy results from a phase 1 study","volume":"8","author":"Budde","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.omton.2025.201097_bib32","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-018-0624-2","article-title":"Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy","volume":"11","author":"Rossari","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omton.2025.201097_bib33","first-page":"85","article-title":"Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure\u2013response analysis of a Phase III study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.omton.2025.201097_bib34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/jcph.1990","article-title":"Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development","volume":"62","author":"Hanley","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.omton.2025.201097_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010702","article-title":"Tailoring CAR surface density and dynamics to improve CAR-T cell therapy","volume":"13","author":"Hinckley-Boned","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201097_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000289196","article-title":"Transcriptional Control of the TNF Gene","volume":"11","author":"Falvo","year":"2010","journal-title":"Curr. Dir. Autoimmun."},{"key":"10.1016\/j.omton.2025.201097_bib39","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V98.5.1480","article-title":"Regulation of interferon-\u03b3 gene expression by nuclear factor of activated T cells","volume":"98","author":"Kiani","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.omton.2025.201097_bib40","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41467-017-00612-6","article-title":"NFATc1 controls the cytotoxicity of CD8+ T cells","volume":"8","author":"Klein-Hessling","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2025.201097_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.omton.2025.201097_bib42","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.omton.2025.201097_bib43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/br.2021.2021117","article-title":"A narrative review on adverse effects of dasatinib with a focus on pharmacotherapy of dasatinib-induced pulmonary toxicities","volume":"56","author":"Nekoukar","year":"2021","journal-title":"Blood Res."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329925001663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T13:37:30Z","timestamp":1778938650000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329925001663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950329925001663"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2025.201097","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of dasatinib and ponatinib for the control of CD123 CAR-T cell functionalities","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2025.201097","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201097"}}